Welcome to our dedicated page for Biomx news (Ticker: PHGE), a resource for investors and traders seeking the latest updates and insights on Biomx stock.
BiomX Inc. (PHGE) generates frequent news flow as a clinical-stage company developing natural and engineered bacteriophage therapies targeting specific pathogenic bacteria. Company press releases and Form 8-K filings describe how BiomX advances phage cocktails and personalized phage treatments for chronic conditions, including cystic fibrosis-related lung infections and diabetic foot disease. News coverage often centers on clinical trial progress, regulatory feedback, financing transactions and strategic updates that can influence the outlook for PHGE stock.
A major theme in BiomX news is the development of its phage product candidates. For BX004, a fixed multi-phage cocktail for cystic fibrosis patients with chronic Pseudomonas aeruginosa infections, the company has reported Phase 1b/2a data, FDA Fast Track and Orphan Drug designations, initiation of a Phase 2b trial, an FDA clinical hold related to a third-party nebulizer device, and ultimately the discontinuation of the Phase 2b study after internal review and Data Monitoring Committee feedback. Separate updates detail European enrollment, FDA correspondence on potential Phase 3 pathways, and safety reviews.
News items also highlight BiomX’s diabetic foot programs. The company has announced statistically significant positive topline Phase 2 results for BX211 in diabetic foot osteomyelitis and subsequent FDA feedback supporting the development pathway for BX011, a next-generation fixed multi-phage cocktail targeting Staphylococcus aureus in diabetic foot infections. Releases describe the rationale for prioritizing DFI, the incorporation of proprietary phages, and the role of non-dilutive funding from U.S. Defense Health Agency and Department of Navy-related sources.
Investors following PHGE can also expect updates on corporate and financial events, such as reverse stock split decisions, private placements of Series Y Convertible Preferred Stock and warrants, lease terminations at subsidiaries, and cost-cutting measures including workforce reductions. Together, these disclosures provide a detailed, evolving picture of BiomX’s clinical pipeline, regulatory interactions, capital structure and strategic alternatives. Bookmark this page to review new PHGE press releases, trial milestones and SEC-reported events as they are published.
BiomX Inc. (NYSE American: PHGE) is set to hold a conference call on November 15, 2021, at 8:00 a.m. EDT to discuss third quarter 2021 financial results and provide business updates. The live audio webcast can be accessed through the company's website.
BiomX is a clinical-stage microbiome company focusing on novel phage therapies targeting pathogenic bacteria, impacting various chronic diseases including inflammatory bowel disease and colorectal cancer.
BiomX announced results from its Phase 2 clinical study of BX001, a topical treatment for acne. The study, involving 140 women with mild-to-moderate acne, met safety and tolerability endpoints with no adverse events reported. Statistically significant improvements were observed in skin appearance metrics, including inflammatory lesion counts (48.3% reduction, p<0.0001) and non-inflammatory lesions (36.3% reduction, p<0.0001). However, no meaningful efficacy difference was noted compared to the vehicle. Subject satisfaction indicated preference for BX001 in reducing redness and improving skin feel.
BiomX (NYSE: PHGE) has entered a licensing agreement with Maruho Co. Ltd., granting Maruho the right of first offer for BX005, a product targeting atopic dermatitis, set to begin after Phase 1/2 trial results in 2022. Additionally, Maruho will invest $3 million in BiomX, supporting the ongoing study. BX005 aims to combat Staphylococcus aureus to improve skin microbiome health. BiomX’s innovative phage-based approach highlights its potential in addressing dermatological issues. The announcement marks a significant collaboration in one of the largest dermatology markets.
BiomX Inc. (NYSE American: PHGE), a clinical-stage microbiome company, announced that CEO Jonathan Solomon will present at three virtual investor events in September 2021. The events include the H.C. Wainwright 23rd Annual Global Investments Conference on September 13, the Oppenheimer Virtual Fall Healthcare Life Science & MedTech Summit on September 20, and the Cantor 2021 Virtual Global Healthcare Conference on September 30. Live webcasts will be available on BiomX's website, and archived materials will be accessible post-event.
BiomX (PHGE) announced a financial update for Q2 2021, highlighting a cash balance of $47.3 million, enabling operations until mid-2023. The company completed a $15 million equity raise and secured a $30 million debt agreement. Four clinical data readouts are expected by mid-2022, including Phase 2 results for acne treatment BX001 due in October. R&D expenses increased to $3.8 million, with a net loss of $7.3 million for the quarter. Upcoming milestones include trials for atopic dermatitis and cystic fibrosis therapies.
BiomX Inc. (PHGE) announced a conference call and webcast on August 16, 2021, at 8:00 a.m. EDT to discuss its second-quarter financial results and provide business updates. The company specializes in developing natural and engineered phage therapies targeting pathogenic bacteria affecting skin and chronic diseases, including inflammatory bowel disease and colorectal cancer. Investors can access the live and archived webcast via BiomX's website.
BiomX (NYSE American: PHGE) has announced a registered direct offering of 3,750,000 shares and warrants for a total expected gross of $15 million. The offering price is set at $4.00 per share, with warrants exercisable for 0.75 shares at $5.00 each, expiring in five years. The proceeds will support clinical trials and general corporate purposes. The closing date is anticipated around July 28, 2021, pending customary conditions. The offering follows an effective shelf registration statement declared by the SEC in December 2020.
BiomX Inc. (PHGE) announced promising preclinical results for its phage therapy candidate, BX005, targeting Staphylococcus aureus in atopic dermatitis. Presented at the Revolutionizing Atopic Dermatitis 2021 Virtual Conference, the results indicate BX005 efficiently eradicates harmful bacteria without mutant strain emergence. CEO Jonathan Solomon emphasized its potential for safer, effective treatment options, especially for children. BiomX expects to share Phase 2 safety and efficacy results in early 2022. The conference presentations occurred on June 13 and will continue on June 17-18, 2021.
BiomX (PHGE) announced promising preclinical results for BX004, a phage therapy targeting Pseudomonas aeruginosa in cystic fibrosis patients. Presented at the 44th European Cystic Fibrosis Conference, the data demonstrated BX004's effectiveness in reducing bacterial levels encased in biofilm, outperforming two antibiotics. Following these results, BiomX plans to advance BX004 to a Phase 1b/2a trial, with outcomes from Part 1 expected in Q1 2022. This advancement indicates the company's commitment to innovative therapies addressing chronic diseases.
BiomX (PHGE) reported Q1 2021 financial results, highlighting progress in clinical trials for its phage therapies. The company completed enrollment of 140 patients in a Phase 2 study of BX001 for acne, with results expected in Q3 and Q4. Positive safety data from BX002 for Inflammatory Bowel Disease prompted a transition to a Phase 1b/2a trial for BX003. Cash on hand was $53.6 million, supporting operations into mid-2022. R&D expenses increased to $5.8 million, and the net loss rose to $8.4 million, compared to $5.9 million in Q1 2020.